GAMMA Investing LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.5% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,083 shares of the biopharmaceutical company’s stock after buying an additional 199 shares during the period. GAMMA Investing LLC’s holdings in Regeneron Pharmaceuticals were worth $1,138,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. West Paces Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares in the last quarter. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $28,000. MCF Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. BOK Financial Private Wealth Inc. acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $37,000. Finally, Criterion Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $37,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN stock traded down $6.92 during mid-day trading on Monday, hitting $1,075.27. The stock had a trading volume of 297,001 shares, compared to its average volume of 469,345. The stock has a market capitalization of $118.48 billion, a price-to-earnings ratio of 31.97, a PEG ratio of 2.34 and a beta of 0.13. The company has a current ratio of 5.96, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $765.28 and a 1-year high of $1,115.00. The company has a fifty day moving average of $1,043.43 and a 200 day moving average of $983.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $8.79 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.38 EPS for the current fiscal year.

Insider Activity

In related news, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the sale, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,074 shares of company stock worth $64,546,123. 7.48% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently commented on REGN. JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,097.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.